Table legends
Table 1. Baseline characteristics of 123 patients with SARS-Cov-2
infection.
Table 2. Summary of adverse events in the safety population.
Table 3. The difference of therapy group and standard group in the
duration of oxygen-support and CoV RNA clearance time.
Table 4. Association of Kaletra/Interferon with the duration of
oxygen-support and CoV RNA clearance in Patients With SARS-CoV-2
infection.